Philip Morris International (PM) Q3 2026 Financial Results Summary
QuoteReporter
Philip Morris International (PM) Q3 2026: Adjusted EPS Growth Amid Currency Headwinds — Positive Outlook
Philip Morris International Inc. (PMI) reported its third-quarter results for 2026, showcasing a mixed performance with notable growth in adjusted earnings per share (EPS) but a decline in reported EPS. The company’s reported diluted EPS fell by 4.9% to $2.12, while adjusted diluted EPS increased by 5.4% to $2.36, reflecting a strong operational performance despite currency fluctuations.
Key Financial Metrics
- Reported Diluted EPS: $2.12, down from $2.23 in Q3 2025 (a decline of 4.9%).
- Adjusted Diluted EPS: $2.36, up from $2.24 in Q3 2025 (an increase of 5.4%).
- Net Revenues: $11.4 billion, an increase of 5.5% (7.1% organically) compared to Q3 2025.
- Gross Profit: $7.9 billion, up 6.7% (8.3% organically) year-over-year.
- Operating Income: Increased by 14.1% (10.5% organically) to $4.9 billion.
Analyst View
This quarter can be viewed positively for shareholders, primarily due to the growth in adjusted EPS and strong revenue performance. The adjusted EPS growth of 5.4% indicates that the core business is performing well, particularly in the smoke-free product segment, which now accounts for over 40% of total net revenues. The increase in net revenues by $600 million or 5.5% year-over-year demonstrates the company's ability to navigate market challenges and capitalize on the growing demand for smoke-free alternatives.
However, the decline in reported EPS highlights the impact of non-cash adjustments, particularly related to fair value adjustments for equity security investments. This discrepancy suggests that while the operational performance is robust, external factors are affecting the bottom line.
Dividend and Shareholder Returns
PMI announced an increase in its regular quarterly dividend by 8.8% to $1.60 per share, translating to an annualized dividend of $6.40 per share. This increase reflects the company's commitment to returning value to shareholders, even amidst fluctuating earnings.
Forward Guidance and Catalysts
Looking ahead, investors should monitor PMI's performance in the fourth quarter, particularly in light of the company's guidance for continued growth in smoke-free products. The company anticipates a full-year adjusted diluted EPS forecast in the range of $8.29 to $8.44, which represents a projected increase of 9.9% to 11.9% compared to the previous year. This guidance is supported by expected organic revenue growth of 5% to 7% and operating income growth of 7% to 9%.
Additionally, PMI's ongoing investments in expanding its smoke-free product portfolio and the recent FDA authorizations for various ZYN products position the company well for future growth. Investors should keep an eye on the impact of geopolitical tensions and energy-related inflation, which could influence operational costs and margins in the upcoming quarters.
In summary, while the reported EPS decline may raise concerns, the underlying growth in adjusted EPS and revenue, coupled with a dividend increase, presents a favorable outlook for PMI's shareholders. The company's strategic focus on smoke-free products and robust market performance are key factors to watch as we move into the next quarter.
Condensed Consolidated Statements of Income (in millions)
Note: All amounts are in millions.
| 2026 | 2025 | Change | |
|---|---|---|---|
| Reported Diluted EPS | $2.12 | $2.23 | (4.9)% |
| Amortization of intangibles | 0.13 | 0.13 | |
| Fair value adjustment | 0.06 | -0.07 | |
| Income tax impact | 0.01 | – | |
| Dutch pension plan buy-out loss | 0.04 | – | |
| Germany excise tax classification | – | 0.10 | |
| litigation charge | – | -0.10 | |
| Tax items | – | -0.14 | |
| Adjusted Diluted EPS | $2.36 | $2.24 | 5.4% |
| Less: Currency | -0.01 | ||
| Adjusted Diluted EPS, excluding Currency | $2.37 | $2.24 | 5.8% |
Condensed Consolidated Balance Sheets (in thousands)
Note: All amounts are in thousands.
| 2026 | 2025 | |
|---|---|---|
| ASSETS | ||
| Current assets | ||
| Cash and cash equivalents | $2,549,000 | $2,200,000 |
| Accounts receivable | $7,458,000 | $6,860,000 |
| Inventories | $4,518,000 | $3,965,000 |
| Other current assets | $1,500,000 | $1,200,000 |
| Total current assets | $16,025,000 | $14,225,000 |
| Non-current assets | ||
| Property, plant and equipment | $10,600,000 | $10,130,000 |
| Intangible assets | $7,250,000 | $6,800,000 |
| Long-term financing receivables | $1,000,000 | $800,000 |
| Other non-current assets | $2,800,000 | $2,600,000 |
| Total non-current assets | $21,650,000 | $20,330,000 |
| Total assets | $37,675,000 | $34,555,000 |
| LIABILITIES AND EQUITY | ||
| Current liabilities | ||
| Accounts payable | $6,200,000 | $5,850,000 |
| Current debt | $2,300,000 | $2,600,000 |
| Other current liabilities | $2,500,000 | $1,600,000 |
| Total current liabilities | $11,000,000 | $10,050,000 |
| Non-current liabilities | ||
| Long-term debt | $11,300,000 | $10,800,000 |
| Other non-current liabilities | $2,000,000 | $1,650,000 |
| Total non-current liabilities | $13,300,000 | $12,450,000 |
| Total liabilities | $24,300,000 | $22,500,000 |
| EQUITY | ||
| Common stock and additional paid-in capital | $7,500,000 | $7,000,000 |
| Retained earnings | $5,875,000 | $5,055,000 |
| Total equity | $13,375,000 | $12,055,000 |
| Total liabilities and equity | $37,675,000 | $34,555,000 |
Disclaimer
The content on MarketsFN.com is provided for educational and informational purposes only. It does not constitute financial advice, investment recommendations, or trading guidance. All investments carry risk and past performance does not guarantee future results. You are solely responsible for your investment decisions and should conduct independent research and consult a qualified financial advisor before acting. MarketsFN.com and its authors are not liable for any losses or damages arising from the use of this information.
